Beijing, Aug 26, 2026 — China’s National Medical Products Administration (NMPA) suspended the import, sale, and use of ophthalmic surgical blades from Laurus Optics Limited after a remote inspection uncovered severe quality management system deficiencies, marking the second foreign device enforcement action within a week as regulators intensify overseas oversight.
Regulatory Snapshot
| Attribute | Detail |
|---|---|
| Issuer | National Medical Products Administration (NMPA) |
| Announcement | 2026 No. 82 |
| Target company | Laurus Optics Limited (亚伦光学仪器有限公司) |
| Product | Ophthalmic Surgical Blades |
| Registration No. | 国械注许20252160016 |
| Inspection type | Remote inspection |
| Effective date | Aug 26, 2026 |
| Legal basis | Medical Device Supervision and Administration Regulations; Medical Device Production Supervision and Administration Measures |
| Scope of suspension | Import, distribution, and clinical use |
Violation Details
The NMPA said its remote review found that Laurus Optics’ quality management system suffered serious deficiencies across critical functions, including key personnel responsibilities, design and development controls, production management, quality control, and product release procedures. Regulators concluded that the lapses created material safety hazards in the finished ophthalmic surgical blades, prompting an immediate market ban to protect public health.
Market Impact Analysis
The suspension halts all commercial activity for Laurus Optics’ sole NMPA-registered device in China, cutting off a supply channel for ophthalmic surgical instruments used in cataract and corneal procedures. The registration prefix “国械注许” indicates the product was approved under the mainland’s special administrative mechanism for Hong Kong, Macau, and Taiwan-registered manufacturers, a category that has faced heightened scrutiny as Beijing tightens quality parity standards across all imported devices.
For Chinese hospitals and distributors, the ban creates an urgent sourcing gap in the ophthalmic blade segment, likely shifting demand to domestic manufacturers or alternative international suppliers with intact NMPA registrations. The enforcement action, announced just one day after the suspension of Avinger peripheral vascular devices, signals a sustained regulatory campaign against foreign manufacturers with quality-system failures rather than isolated product defects.
Forward-Looking Statement
Industry analysts expect Laurus Optics to face a protracted remediation cycle requiring comprehensive quality system overhauls, third-party audits, and a rescheduled NMPA inspection before reinstatement is considered. The back-to-back enforcement actions against foreign device makers in late August suggest regulators are deploying remote inspection capabilities at scale to scrutinize overseas manufacturing sites without the logistical burden of on-site visits. Companies with “国械注许” registrations—particularly smaller specialty instrument firms—should treat this case as a warning to audit their China-facing quality documentation and personnel qualification records proactively. The suspension is likely to remain in place through at least the first quarter of 2027, barring an unusually rapid corrective action submission.-China Health Reform Pulse
Policy Source: https://www.nmpa.gov.cn/ylqx/ylqxggtg/20260827103916159.html